# Lisata Therapeutics (LSTA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/LSTA
## Company Profile
- Ticker: LSTA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.2 USD
- Market cap: 31690240.68 USD
- Last updated: 2026-10-08
## Business Overview
Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.
## Why The Stock Is Moving

Following the latest company update, “Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors”, LSTA closed up 2.56% at $1.20 on Oct 8, 2026. The move occurred in the trading session associated with this company update.

## Geographic Base

Lisata is headquartered in the United States and listed on NASDAQ, with a small-cap oncology biotechnology profile. It sits in the development-stage cancer and drug-delivery segment.

## Business Model

The company depends on clinical data, partnership potential, and the ability to prove that its platform can improve outcomes in solid tumors. Investors generally watch trial updates, strategic collaborations, and capital needs.

## Landscape Position

Lisata occupies a specialized precision-oncology niche within biotech. The stock is driven by the market's view of whether its delivery-focused strategy can create meaningful clinical differentiation.

## Future Catalysts

- Lisata’s catalysts are certepetide and the pancreatic-cancer / solid-tumor development path, where the next update matters a lot. The company still needs stronger clinical proof.

## Recent News
- 2026-10-08 12:00 EST — [Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-new-method-of-use-patent-granted-for-certepetide-i-eb22245a) — Source: Lisata Therapeutics
- 2026-10-05 12:00 EST — [Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly](https://biopharmsignal.com/news/LSTA/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-d-0f7957e8) — Source: Lisata Therapeutics
- 2026-09-24 12:00 EST — [Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026](https://biopharmsignal.com/news/LSTA/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-upcoming-late-b-8cc5aeb5) — Source: Lisata Therapeutics
- 2026-09-17 13:27 EST — [Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million--686a6c23) — Source: Lisata Therapeutics
- 2026-08-04 11:00 EST — [Lisata Therapeutics Provides Update Following Termination of Merger Agreement](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-provides-update-following-termination-of-merger-agreement-b0ae6a2c) — Source: Lisata Therapeutics